Expanding the scope and visibility of ambulatory stewardship programs with novel coronavirus disease 2019 (COVID-19) therapeutics

Hongkai Bao; Yi Guo; Mei H. Chang; Terrence McSweeney; Austin M. Golia; Kelsie Cowman; Rachel Bartash; Brenda I. Anosike; Priya Nori

doi:10.1017/ash.2022.52

Expanding the scope and visibility of ambulatory stewardship programs with novel coronavirus disease 2019 (COVID-19) therapeutics

Hongkai Bao, Yi Guo, Mei H. Chang, Terrence McSweeney, Austin M. Golia, Kelsie Cowman, Rachel Bartash, Brenda I. Anosike, Priya Nori

Research output: Contribution to journal › Review article › peer-review

3 Scopus citations

Abstract

Antimicrobial stewardship programs (ASPs) can be expanded to the outpatient setting to serve as a first line of defense against coronavirus disease 19 (COVID-19) hospitalizations and to reduce the burden on emergency departments and acute-care hospitals. Given the numerous emergency use authorizations of monoclonal antibodies and oral antivirals, ASPs possess the expertise and leadership to direct ambulatory COVID-19 initiatives and transform it into a predominantly outpatient illness. In this review, we summarize the critical role and benefits of an ASP-championed ambulatory COVID-19 therapeutics program.

Original language	English (US)
Article number	e73
Journal	Antimicrobial Stewardship and Healthcare Epidemiology
Volume	2
Issue number	1
DOIs	https://doi.org/10.1017/ash.2022.52
State	Published - Apr 29 2022

ASJC Scopus subject areas

Microbiology (medical)
Infectious Diseases
Epidemiology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1017/ash.2022.52

Cite this

@article{36b52e22e0664714bb79f73f08081015,

title = "Expanding the scope and visibility of ambulatory stewardship programs with novel coronavirus disease 2019 (COVID-19) therapeutics",

abstract = "Antimicrobial stewardship programs (ASPs) can be expanded to the outpatient setting to serve as a first line of defense against coronavirus disease 19 (COVID-19) hospitalizations and to reduce the burden on emergency departments and acute-care hospitals. Given the numerous emergency use authorizations of monoclonal antibodies and oral antivirals, ASPs possess the expertise and leadership to direct ambulatory COVID-19 initiatives and transform it into a predominantly outpatient illness. In this review, we summarize the critical role and benefits of an ASP-championed ambulatory COVID-19 therapeutics program.",

author = "Hongkai Bao and Yi Guo and Chang, {Mei H.} and Terrence McSweeney and Golia, {Austin M.} and Kelsie Cowman and Rachel Bartash and Anosike, {Brenda I.} and Priya Nori",

note = "Publisher Copyright: {\textcopyright} 2022 The Author(s). Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America.",

year = "2022",

month = apr,

day = "29",

doi = "10.1017/ash.2022.52",

language = "English (US)",

volume = "2",

journal = "Antimicrobial Stewardship and Healthcare Epidemiology",

issn = "2732-494X",

publisher = "Cambridge University Press",

number = "1",

}

TY - JOUR

T1 - Expanding the scope and visibility of ambulatory stewardship programs with novel coronavirus disease 2019 (COVID-19) therapeutics

AU - Bao, Hongkai

AU - Guo, Yi

AU - Chang, Mei H.

AU - McSweeney, Terrence

AU - Golia, Austin M.

AU - Cowman, Kelsie

AU - Bartash, Rachel

AU - Anosike, Brenda I.

AU - Nori, Priya

PY - 2022/4/29

Y1 - 2022/4/29

N2 - Antimicrobial stewardship programs (ASPs) can be expanded to the outpatient setting to serve as a first line of defense against coronavirus disease 19 (COVID-19) hospitalizations and to reduce the burden on emergency departments and acute-care hospitals. Given the numerous emergency use authorizations of monoclonal antibodies and oral antivirals, ASPs possess the expertise and leadership to direct ambulatory COVID-19 initiatives and transform it into a predominantly outpatient illness. In this review, we summarize the critical role and benefits of an ASP-championed ambulatory COVID-19 therapeutics program.

AB - Antimicrobial stewardship programs (ASPs) can be expanded to the outpatient setting to serve as a first line of defense against coronavirus disease 19 (COVID-19) hospitalizations and to reduce the burden on emergency departments and acute-care hospitals. Given the numerous emergency use authorizations of monoclonal antibodies and oral antivirals, ASPs possess the expertise and leadership to direct ambulatory COVID-19 initiatives and transform it into a predominantly outpatient illness. In this review, we summarize the critical role and benefits of an ASP-championed ambulatory COVID-19 therapeutics program.

UR - http://www.scopus.com/inward/record.url?scp=85130100368&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85130100368&partnerID=8YFLogxK

U2 - 10.1017/ash.2022.52

DO - 10.1017/ash.2022.52

M3 - Review article

AN - SCOPUS:85130100368

SN - 2732-494X

VL - 2

JO - Antimicrobial Stewardship and Healthcare Epidemiology

JF - Antimicrobial Stewardship and Healthcare Epidemiology

IS - 1

M1 - e73

ER -

Expanding the scope and visibility of ambulatory stewardship programs with novel coronavirus disease 2019 (COVID-19) therapeutics

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this